Michael J. Tomsicek
2020 - CRISPR Therapeutics AG
In 2020, Michael J. Tomsicek earned a total compensation of $2.6M as Chief Financial Officer at CRISPR Therapeutics AG, a 35% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $244,760 |
|---|---|
| Option Awards | $1,563,531 |
| Salary | $422,000 |
| Stock Awards | $379,695 |
| Other | $11,400 |
| Total | $2,621,386 |
Tomsicek received $1.6M in option awards, accounting for 60% of the total pay in 2020.
Tomsicek also received $244.8K in non-equity incentive plan, $422K in salary, $379.7K in stock awards and $11.4K in other compensation.
Rankings
In 2020, Michael J. Tomsicek's compensation ranked 4,365th out of 13,090 executives tracked by ExecPay. In other words, Tomsicek earned more than 66.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,365 out of 13,090 | 67th |
Division Manufacturing | 1,770 out of 5,620 | 69th |
Major group Chemicals And Allied Products | 693 out of 2,253 | 69th |
Industry group Drugs | 593 out of 1,953 | 70th |
Industry Biological Products, Except Diagnostic Substances | 137 out of 411 | 67th |
Source: SEC filing on April 28, 2021.
Tomsicek's colleagues
We found four more compensation records of executives who worked with Michael J. Tomsicek at CRISPR Therapeutics AG in 2020.
News
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2021 pay jumps 87% to $17M
April 25, 2022
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2020 pay falls 44% to $9.1M
April 28, 2021
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2019 pay jumps 67% to $16M
April 24, 2020
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2018 pay jumps 40% to $9.7M
April 30, 2019
ABIOMED CEO Michael Minogue's 2018 pay slips 16% to $10M
June 22, 2018